A novel small compound TOIDC suppresses lipogenesis via SREBP1-dependent signaling to curb MAFLD

BACKGROUND: Inhibition of hepatic lipogenesis is widely regarded as an effective treatment for metabolic-associated fatty liver disease (MAFLD), although numerous related drugs have failed to reach clinical application. The goal of this study is to identify a novel small compound that can effectivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Yaodi, Yao, Zhi, Zhou, Junyi, Yu, Miao, Chen, Suzhen, Yuan, Yanmei, Han, Liu, Jiang, Liqin, Liu, Junli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727880/
https://www.ncbi.nlm.nih.gov/pubmed/36474251
http://dx.doi.org/10.1186/s12986-022-00713-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727880/
https://www.ncbi.nlm.nih.gov/pubmed/36474251
http://dx.doi.org/10.1186/s12986-022-00713-0

Ejemplares similares